


# What can we learn from cancer genomes?



## Introduction to cancer genomics

**What is cancer?**

Cancer is a group of diseases characterized by the **abnormal growth and spread of cells**.

Most cancers are caused by genetic alterations that can be:

- Inherited → germline
- Acquired during life → somatic

Most cancers are driven by somatic mutations.

**Can Darwin teach us something about cancer?**

**YES!**

Cancer evolves as a Darwinian evolutionary process.

Here snails and cells behave the same way.  
**The more adapted the more survive.**

**IMPORTANT**

**Cancer drivers** are the genomic alterations that confer selective advantage to the cell.


**Driver genes** are those that carry driver mutations.

★ Driver mutation  
● Passenger mutation

## The identification of cancer drivers


### HOW DO WE IDENTIFY CANCER DRIVERS?

Sequencing of tumour samples to identify cancer somatic mutations




The main problem is that **tumours genomes have thousand of somatic mutations**, and only an **average on 4.6 of the are drivers**.

### 1 Signals of positive selection



Driver genes can be detected through **signals of positive selection** (special patterns in the distribution of mutations that appear as a result of tumorigenesis → **selective advantage**). That signals are **complementary** (not all driver genes have the 3 signals). To identified them we test if **what we observe is expected to occur by chance** (neutral evolution)

### 2 A method in depth: Oncodrive CLUSTL




OncodriveCLUSTL is a sequence-based clustering method that **identifies drivers in protein-coding regions**.

### 3 The pipeline: IntOGen + boostDM

Since the signals are complementary, the idea would be to merge all these methods.


**IntOGen: One method to rule them all**

Using sequences of patients of different projects, **IntOGen uses 7 methods** (2 based on recurrence, 3 based on clustering and some based on functional impact) to identify driver genes.



**BUT... not all mutations in driver genes are driver mutations!**

They are detected by **boostDM**, a machine learning algorithm that can predict driver mutations in human cancers.



### PERSPECTIVES

The number of sequencings of different types of cancers will increase, which will allow identify driver mutations in less common cancers.

## Clinical application: Cancer Genome Interpreter

**Cancer Genome Interpreter** is a algorithm very useful to clinics, because of the **easy interpretation of the mutations** of an specific patient. Clinics can introduce the mutations that the patients have in their tumours and Cancer Genome Interpreter **identifies which ones are drivers and passengers**. That knowledge allows to choose **the most effective therapy** to each patient (personalize therapy).

ALTERATIONS

PRESCRIPTIONS

Biomarkers

Bioactivities

Show entries with:

mutations described as biomarkers for the selected tumor type

mutations in genes described as biomarkers with a different annotation change

mutations described as biomarkers for a different tumor type

mutations in genes described as biomarkers upon other alteration types

Sample ID	Observed alteration	Drugs	Effect	Tumor type	Level of evidence	Reference	Tumor match	Biomarker match
corred_01	BRAF V600E	Cetuximab, Panitumumab	Resistant	COREAD	Early trials	PMID: 20619770 PBL	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
corred_01	BRAF V600E	Vemurafenib	No response	COREAD	Early trials	PMID: 26287891	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
corred_01	BRAF V600E	Irinotecan + Cetuximab + Vemurafenib	Responsive	COREAD	Guidelines	NCIN guidelines	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
corred_01	BRAF V600E	Panitumumab + Dabrafenib + Trametinib	Responsive	COREAD	Early trials	ASCO 2015 label 103...	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
corred_01	BRAF V600E	Panitumumab + Dabrafenib + Alpelisib	Responsive	COREAD	Early trials	PMID: 26363909	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
corred_02	APC R1450* + G	Tyrosine inhibitor	Responsive	COREAD	Pre-clinical	PMID: 22460713 PBL	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
corred_05	RNF43 A169T	Perceptase inhibitor	Responsive	COREAD	Case report	ENA 2015 label CAS...	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>

Reference 6